FoundationOne® Analysis Platform + AVENIO Connect Software

Secondary analysis and data management software



Thoroughly validated variant calling knowledgebase

- Built on insights from Foundation Medicine's experience in profiling over 1.3 million+ samples.[1]
- Continuously evolving based on evidence compiled from databases such as COSMIC, dbSNP, gnomAD, 1000 Genomes.[2]

Cloud-based computing for efficient analysis

- Converts uploaded BCL files to FASTQ, demultiplexes reads, and downsamples.*
- Enables regular updates to minimize downtime and manual intervention.
- Allows for seamless hardware integration.

Broad genomic coverage

- Identifies all four types of genomic variants including Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, and Rearrangements.[3,4]
- Calculates genomic signatures such as TMB, MSI, gLOH, and newly added HRD signature (HRDsig).[3-5]
- Variant calls in all captured regions, not limited to pre-defined set of hotspots.

Confidence in high-quality results

- 14+ QC metrics, including median coverage and potential contamination, used to assess data quality.[4]
- Enables users to filter and annotate genomic data for criticality, relevance and biological significance.[3]

AVENIO Tumor Tissue CGP Kit V2 is For Research Use Only. Not for use in diagnostic procedures.

TMB, tumor mutational burden. MSI, Microsatelite instability. gLOH, genomic loss of heterozygosity. HRD, homologous recombination deficiency. QC, quality control.
* BCL files are the raw data files generated by the Illumina sequencers. FASTQ format is a text-based format for storing both a biological sequence and its corresponding quality scores.

AVENIO Tumor Tissue CGP Kit V2
Powered by **FOUNDATION MEDICINE**

Gain access to clear information and results

Web application for download of analysis output files

- VCF (SNVs and InDels)
- JSON (CNAs, REs, TMB, MSI, gLOH and HRDsig)
- CSV (QC metrics & variants combined)
- BAM (alignment file)



1. Foundation Medicine Biopharma services. Available at: https://www.foundationmedicine.com/info/biopharma-overview (Accessed July 2024).
2. Foundation Medicine® About Us. Available at: https://www.foundationmedicine.com/info/detail/our-story (Accessed July 2024).
3. Choi et al. Evolution of a Comprehensive Genomic Profiling (CGP) Kit to Simplify Workflows and Detect Homologous Recombination Deficiency. Poster presented at Association of Molecular Pathology Europe, June 2024.
4. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use June 2024.
5. Chen KT et al. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. Oncologist. 2023 Aug 3;28(8):691-698. doi: 10.1093/oncolo/oyad178.

AVENIO Tumor Tissue CGP Kit V2 is For Research Use Only. Not for use in diagnostic procedures.

SNV=Single Nucleotide Variant, InDel=Insertion and Deletion, CNA=Copy Number Alteration, TMB=Tumor Mutational Burden, MSI=Microsatellite Instability, gLOH=genomic Loss of Heterozygosity, HRDsig=Homologous Recombination Deficiency Signature, QC=Quality Control

For more information on FoundationOne® Analysis Platform and AVENIO Connect Software please reach out to your local Roche representative.

MC-14459 July 2024

AVENIO Tumor Tissue CGP Kit V2
Powered by **FOUNDATION MEDICINE**